Revvity, Inc.
Revvity, Inc. is classed by the SEC under Laboratory Analytical Instruments (industry code 3826), based in Waltham, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-28, it reported revenue of $2.9 billion and a profit of $241 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3826, Laboratory Analytical Instruments); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.2 out of ten, 9 of 9 metrics filed: past 6.5 out of ten, present 7.0 out of ten, future 4.9 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.0 out of ten. No warning events in its filings since 2017. 80th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 4.4 out of ten. +3.4% a year over 10 filed years; profitable in 10 of 10. 44th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 8.5 out of ten. Share count shrank 2.7% a year. 100% of cash flow returned. Insiders: 17 sales, 0 purchases. 85th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 7.3 out of ten. ROE 3%: 3¢ of profit per shareholder dollar. Leverage 40%: owes 40¢ per asset dollar. 73rd percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 5.2 out of ten. top 48% of 21 in its family; net margin 8.4%. 52nd percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 8.9 out of ten. top 11% of 21 in its family for leadership; chief executive since 2020. 89th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.2 out of ten. bottom 42% of 21 in its family for room to expand. 42nd percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 5.2 out of ten. top 48% of 21 in its family for growth drivers. 52nd percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 5.8 out of ten. top 42% of 20 in its family for expectations against reality. 58th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-24 for the period ended 2025-12-28 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-11 for the period ended 2026-07-05 (on EDGAR). Newest results release: Form 8-K filed 2026-08-04 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-10-07. Filings on record since 1994. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Life Sciences 50%, Diagnostics 50%. By geography: United States 39%, Other International 35%, China 15%, Germany 6%, United Kingdom 4%. As tagged in its annual report (Form 10-K, filed 2026-02-24).
Who runs it
Singh, Prahlad R. (President, Chief Executive Officer and Director); Krakowiak, Maxwell (Senior Vice President and Chief Financial Officer); Vohra, Tajinder S (Senior Vice President, Global Operations); Goldberg, Joel S (Senior Vice President, Administration, General Counsel and Secretary); Victor, Miriame (Senior Vice President, Chief Commercial Officer); Gonzales, Anita (VP and CAO); Michas, Alexis P (director); Barrett, Peter (director); Chapin, Samuel R. (director); Klobuchar, Michael A (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-02.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.